Compare Fubotv Inc (FUBO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Fubotv Inc trades at $9.38 (market cap $1.02B), while Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 74.6× Fubotv Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| FUBO | REGN | |
|---|---|---|
Market Cap | $1.02B | $76.14B |
Volume | 978,631 | 500,239 |
Sector | Media | Health |
52-Week High | $48.96 | $852.03 |
52-Week Low | $8.09 | $557.73 |
Typical Hold Time | 35 Days | 107 Days |
Enterprise Value | $1.19B | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.25, up 4.76% today, showing technical bearish signals with mixed earnings performance. The company reported Q2 2026 EPS of -$0.25, beating expectations, but missed in Q4 2025. Revenue growth has been strong, reaching $1.62B in 2024 with improving profit margins. Recent developments include new sports streaming agreements and Disney partnership integration driving subscriber growth.
FUBO presents a speculative opportunity with deep valuation discounts (P/E 2.43, P/S 0.19) but faces execution risks amid persistent cash burn. Analyst consensus is mixed with 47% buy ratings and $63.38 price target, representing significant upside potential if turnaround succeeds. Key risks include competitive pressure and path to sustained profitability.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
